The diffuse large B-cell lymphoma - where do we stand now in everyday clinical practice

Swerdlow SH, Campo E, Harris NL, Pileri SA, Stein H, Thiele J, et al, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th edition. Lyon, France: International Agency for Research on Cancer; 2008.Search in Google Scholar

Žakelj Primic M, Bračko M, Pompe-Kirn V, Zakotnik B, editors. Rak v Sloveniji 2007. Ljubljana: Onkološki inštitut Ljubljana, Epidemiologija in register raka, Register raka Republike Slovenije, 2010.Search in Google Scholar

Shipp M, Harrington D, Anderson J, Armitage JO, Bonadonna G, Brittinger G, et al. A predictive model for aggressive non-Hodgkincs lymphomas. N Engl J Med 1993; 329: 987-94.10.1056/NEJM1993093032914028141877Search in Google Scholar

Strojan-Flezar M, Lavrencak J, Zganec M, Strojan P. Image cytometric nuclear texture features in inoperable head and neck cancer: a pilot study. Radiol Oncol 2011; 45: 40-50.10.2478/v10019-011-0002-y342372022933933Search in Google Scholar

Velnar T, Smrdel U, Popovic M, Bunc G. Genetic markers in oligodendroglial tumours. Radiol Oncol 2010; 44: 13-8.10.2478/v10019-010-0007-y342367522933885Search in Google Scholar

Cvetkovic RS, Perry CM. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Drugs 2006; 66: 791-820.10.2165/00003495-200666060-0000516706552Search in Google Scholar

Molina A. A decade of rituximab: improving survival outcomes in nonHodgkin's lymphoma. Annu Rev Med 2008; 59: 237-50.10.1146/annurev.med.59.060906.22034518186705Search in Google Scholar

Jezeršek Novaković B, Benigar A. Treatment of non-Hodgkin's lymphomas with rituximab in Slovene patients. Med Oncol 2010; 27: 167-76.10.1007/s12032-009-9188-x19263255Search in Google Scholar

Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, Pfreundschuh M, et al. Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol 2010; 28: 2373-80.10.1200/JCO.2009.26.249320385988Search in Google Scholar

Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised International Prognostic Index is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007; 109: 1857-61.10.1182/blood-2006-08-03825717105812Search in Google Scholar

Tilly H, Dreyling M. Diffuse large B-cell non-Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21(Suppl 5): 172-4.10.1093/annonc/mdq20320555073Search in Google Scholar

Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol 1999: 17: 1244-53.10.1200/JCO.1999.17.4.124410561185Search in Google Scholar

Cheson BD. New staging and response criteria for non-Hodgkin lymphoma and Hodgkin lymphoma. Radiol Clin North Am 2008; 46: 213-23.10.1016/j.rcl.2008.03.003Search in Google Scholar

Pettengell R, Linch D. Position paper on the therapeutic use of rituximab in CD20-positive diffuse large B-cell non-Hodgkin's lymphoma. Br J Haematol 2003; 121: 44-8.10.1046/j.1365-2141.2003.04274.xSearch in Google Scholar

Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-42.10.1056/NEJMoa011795Search in Google Scholar

Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005; 23: 5027-33.10.1200/JCO.2005.09.137Search in Google Scholar

Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005; 23: 4117-26.10.1200/JCO.2005.09.131Search in Google Scholar

Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 3121-7.10.1200/JCO.2005.05.1003Search in Google Scholar

Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379-91.10.1016/S1470-2045(06)70664-7Search in Google Scholar

Coiffier B, Thieblemont C, Van Den Neste E, Lepeu G, Plantier I, Castaigne S, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010; 116: 2040-5.10.1182/blood-2010-03-276246295185320548096Search in Google Scholar

Horvat M, Jezeršek Novaković B. Effect of response quality and line of treatment with rituximab on overall and disease-free survival of patients with B-cell lymphoma. Radiol Oncol 2010, 44: 232-8.10.2478/v10019-010-0044-6342370322933921Search in Google Scholar

Kovač V, Smrdel U. Meta-analyses of clinical trials in patients with non-small cell lung cancer. Neoplasma 2004; 51: 334-40.Search in Google Scholar

Ott G, Ziepert M, Klapper W, Horn H, Szczepanowski M, Bernd HW, et al. Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL. Blood 2010; 116: 4916-25.10.1182/blood-2010-03-27676620736456Search in Google Scholar

Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503-11.10.1038/35000501Search in Google Scholar

Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008; 359: 2313-23.10.1056/NEJMoa0802885Search in Google Scholar

Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008; 9: 105-16.10.1016/S1470-2045(08)70002-0Search in Google Scholar